A Phase I Study of Quadrivalent HPV Recombinant Vaccine

Summary

To evaluate the safety and primary immunogenicity of the quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (hansenula polymorpha) in Chinese female subjects aged 9-45 years.

Timeline

Start

2016-12

Primary completion

2017-10

Completion

2018-08

Drugs

Indications